Literature DB >> 11080525

CGRP and adrenomedullin receptor populations in human cerebral arteries: in vitro pharmacological and molecular investigations in different artery sizes.

A Sams1, E Knyihár-Csillik, J Engberg, D Szok, J Tajti, I Bodi, L Edvinsson, L Vécsei, I Jansen-Olesen.   

Abstract

The aim of the present study was to determine functional and molecular characteristics of receptors for calcitonin gene-related peptide (CGRP) and adrenomedullin in three different diameter groups of lenticulostriate arteries. Furthermore, the presence of perivascular neuronal sources of CGRP was evaluated in these arteries. In the functional studies, in vitro pharmacological experiments demonstrated that both CGRP and adrenomedullin induce alpha-CGRP-(8-37) sensitive vasodilation in artery segments of various diameters. The maximal amounts of vasodilation induced by CGRP and adrenomedullin were not different, whereas the potency of CGRP exceeded that of adrenomedullin by 2 orders of magnitude. Significant negative correlations between artery diameters and maximal responses were demonstrated for CGRP and adrenomedullin. In addition, the potency of both peptides tended to increase in decreasing artery diameter. In the molecular experiments, levels of mRNAs encoding CGRP receptors and receptor subunits were compared using reverse transcriptase polymerase chain reactions (RT-PCR). The larger the artery, the more mRNA encoding receptor activity-modifying proteins 1 and 2 (RAMP1 and RAMP2) was detected relative to the amount of mRNA encoding the calcitonin receptor-like receptor. By immunohistochemistry, perivascular CGRP containing nerve fibres were demonstrated in all the investigated artery sizes. In conclusion, both CGRP and adrenomedullin induced vasodilation via CGRP receptors in human lenticulostriate artery of various diameter. The artery responsiveness to the CGRP receptor agonists increased with smaller artery diameter, whereas the receptor-phenotype determining mRNA ratios tended to decrease. No evidence for CGRP and adrenomedullin receptor heterogeneity was present in lenticulostriate arteries of different diameters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080525     DOI: 10.1016/s0014-2999(00)00781-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37).

Authors:  Raphaela Verheggen; Katja Bumann; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  Receptor activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-related peptide and inhibits angiotensin II-induced vascular dysfunction.

Authors:  Sophocles Chrissobolis; Zhongming Zhang; Dale A Kinzenbaw; Cynthia M Lynch; Andrew F Russo; Frank M Faraci
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

3.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

4.  Noncompetitive antagonism of BIBN4096BS on CGRP-induced responses in human subcutaneous arteries.

Authors:  Majid Sheykhzade; Henrik Lind; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2004-10-11       Impact factor: 8.739

Review 5.  Mechanisms involved in the cerebrovascular dilator effects of cortical spreading depression.

Authors:  David W Busija; Ferenc Bari; Ferenc Domoki; Takashi Horiguchi; Katsuyoshi Shimizu
Journal:  Prog Neurobiol       Date:  2008-09-12       Impact factor: 11.685

Review 6.  Neuropeptides and the Nodes of Ranvier in Cranial Headaches.

Authors:  Jacob C A Edvinsson; Kristian A Haanes; Lars Edvinsson
Journal:  Front Physiol       Date:  2022-01-12       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.